By: Jason M. Broderick From: targetedonc.com Combining Neratinib (Nerlynx) with capecitabine (Xeloda) showed a 24% reduction in the risk of disease progression or death compared with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 …
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with …
Study uncovers unknown pathway for breast cancer recurrence
From: business-standard.com The researchers have tracked treatment-resistant cancer cells that grow and spread after the breast cancer treatment. For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs. Now a team of researchers has filled …
Breast cancer study by UCR medical student could help patients live longer
By: Iqbal Pittalwala From: ucr.edu A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or …
Breast cancer drug approved for Australia
By: AAP From: 9news.com.au Kate Harper wants to be around to watch her two young twin sons grow up. That’s why, after grappling with the feeling of helplessness that came with being diagnosed with breast cancer, she made a commitment. “I said right from the start – and my husband’s in agreement as well – that we would attack everything …
Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients Granted FDA Approval
By: Jennifer Barrett From: pharmacytimes.com Officials with the FDA have approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) subcutaneous injection for certain patients with HER2-positive early and metastatic breast cancer, according to a press release. Trastuzumab and hyaluronidase-oysk is indicated for patients with early disease in combination with chemotherapy, and metastatic disease in combination with paclitaxel, or alone in patients who …
Collaboration Promises Better, More Accurate Breast Cancer Diagnostics
From: PR Newswire Data-sharing result s in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results. The Health Exchange Market, or T.H.E.M.™, together with LabCorp, Konica Minolta, Inc. University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio …
uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.
From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …
Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …
New cancer vaccine may tackle HER2-positive tumors
By: Ana Sandoiu From: medicalnewwstoday.com New research shows that a new cancer vaccine may be effective for treating a range of HER2-positive cancers, including the more aggressive HER2-positive breast cancer. Cancer that is human epidermal growth factor 2 (HER2)-positive holds too much of the protein on the surface of its cells. In HER2’s role as a growth factor, normal levels …